generation-high-throughput-three-dimensional-tumor-spheroids-for-drug

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Cancer cells have routinely been cultured in two dimensions (2D) on a plastic surface. This technique, however, lacks the true environment a tumor mass is ...

Novartis Institutes for BioMedical Research

Elucidation of the mutational landscape of human cancer has progressed rapidly and been accompanied by the development of therapeutics targeting mutant oncogenes. However, a comprehensive mapping of cancer dependencies has lagged behind and the discovery of therapeutic targets for counteracting tumor suppressor gene loss is needed. To identify vulnerabilities relevant to specific cancer subtypes, we conducted a large-scale RNAi screen in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines. We describe findings of this screen, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features. In addition, we describe robust gene-interaction networks recapitulating both protein complexes and functional cooperation among complexes and pathways. This dataset along with a web portal is provided to the community to assist in the discovery and translation of new therapeutic approaches for cancer.

Serena J. Silver

Oncology Drug Discovery: Molecular Pharmacology

Novartis Institutes for BioMedical Research

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Serena J. Silver

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Oncology Drug Discovery: Molecular Pharmacology

Novartis Institutes for BioMedical Research

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Oncology Drug Discovery: Molecular Pharmacology